Oh, Kyoung-Seok
Nam, Ah-Rong
Bang, Ju-Hee
Seo, Hye-Rim
Kim, Jae-Min
Yoon, Jeesun
Kim, Tae-Yong
Oh, Do-Youn http://orcid.org/0000-0003-1663-9901
Funding for this research was provided by:
Seoul National University Hospital (03-2019-0220)
Korea Health Industry Development Institute (06-2016-2920)
AstraZeneca (06-2016-2920)
National Research Foundation of Korea (2021R1A2C2007430)
Article History
Received: 20 October 2021
Revised: 8 June 2022
Accepted: 13 June 2022
First Online: 7 July 2022
Competing interests
: Oh DY: Consultant or advisory board member of AstraZeneca, Novartis, Genentech/Roche, Merck Serono, Bayer, Taiho, ASLAN, Halozyme, Zymeworks, BMS/Celgene, BeiGene, Basilea, Turning Point, and Yuhan. Research grant from AstraZeneca, Novartis, Array, Eli Lilly, Servier, BeiGene, MSD, and Handok.